omacetaxine mepesuccinate
FDA grants Fast Track status for peanut allergy immunotherapy
The treatment uses peptides designed to retrain the immune system to tolerate peanuts
Permission to pause: making treatment breaks part of the cancer care conversation
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
Novartis’ Pluvicto approved by FDA for metastatic hormone-sensitive prostate cancer
More than 186,000 men are diagnosed each year with mHSPC globally
Key takeaways from ASCO® 2026
Following ASCO® 2026, Inizio's experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year's congress revealed for pharmaceutical organisations. Together, they...
Bristol Myers Squibb’s New Drug Application for mezigdomide accepted by FDA
Mezigdomide improves progression-free survival in patients with relapsed or refractory multiple myeloma
Teva submits FDA application for paediatric Tourette syndrome therapy
Ecopipam could become the first new FDA-approved treatment for paediatric Tourette syndrome in over ten years
Roche’s Enspryng given FDA Priority Review as thyroid eye disease treatment
This is the first and only at-home subcutaneous treatment option for this disease
Regeneron’s New Drug Application for cemdisiran accepted for review by FDA and EMA
Globally, around 150 to 200 out of every million people have myasthenia gravis
Webcast | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026
Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.
Roche’s Tecentriq gets FDA Priority Review for specific stage 3 colon cancer
Over one million people are diagnosed globally each year and around 30% of stage 3 patients relapse within five years
Lilly’s Ebglyss approved by FDA as maintenance dose for atopic dermatitis
This new option for patients allows for as few as six maintenance injections per year
Pfizer and Innovent Biologics agree on deal worth up to $10.5bn
The companies plan to research and develop 12 new cancer treatments